Allogene Therapeutics, the new and buzzy CAR-T cancer therapy startup backed by former Kite Pharma CEO Arie Belldegrun, is recruiting veteran Cowen biotech analyst Eric Schmidt to become its new chief financial officer, STAT has learned.

Schmidt confirmed to STAT that he is considering a job offer with Allogene but “no decision has been made” on whether he will accept. Schmidt says he informed his higher-ups at Cowen last week that he was considering a move.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy